• 제목/요약/키워드: Primary drug resistance

검색결과 64건 처리시간 0.028초

Effect of MUC1 siRNA on Drug Resistance of Gastric Cancer Cells to Trastuzumab

  • Deng, Min;Jing, Da-Dao;Meng, Xiang-Jun
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권1호
    • /
    • pp.127-131
    • /
    • 2013
  • Trastuzumab is the first molecular targeting drug to increase the overall survival rate in advanced gastric cancer. However, it has also been found that a high intrinsic or primary trastuzumab resistance exists in some proportion of gastric cancer patients. In order to explore the mechanism of resistance to trastuzumab, firstly we investigated the expression of MUC1 (membrane-type mucin 1) in gastric cancer cells and its relationship with drug-resistance. Then using gene-silencing, we transfected a siRNA of MUC1 into drug-resistant cells. The results showed the MKN45 gastric cell line to be resistant to trastuzumab, mRNA and protein expression of MUC1 being significantly upregulated. After transfection of MUC1 siRNA, protein expression of MUC1 in MKN45cells was significantly reduced. Compared with the junk transfection and blank control groups, the sensitivity to trastuzumab under MUC1 siRNA conditions was significantly increased. These results imply that HER2-positive gastric cancer cell MKN45 is resistant to trastuzumab and this resistance can be cancelled by silencing expression of the MUC1 gene.

Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children

  • Hong, Suk Jin;Choe, Byung-Ho
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제15권2호
    • /
    • pp.63-73
    • /
    • 2012
  • Development of antiviral resistance to lamivudine is the most important factor for the treatment failure. It is necessary to establish proper guidelines to overcome drug resistance for children with chronic hepatitis B. Primary treatment with lamivudine should be considered if patients are in immune-clearance phase and have persistently elevated ALT levels more than twice the upper limit of normal value. Before initiating the therapy, careful consideration of the patient's status is required to exclude abnormal liver function tests due to other causes. The treatment option should be carefully decided to suppress the viral replication effectively. To obtain good compliance, clinicians should educate patients and their parents. Appropriate monitoring for virologic breakthrough and genotypic resistance is important in deciding to change the treatment plan. Sequential monotherapy should be avoided and a combination of drugs in other categories is recommended. New antiviral agents, such as entecavir and tenofovir, which have high potency and high genetic barrier, are soon expected to be available for use with children.

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors

  • Yang, Sei-Hoon
    • Tuberculosis and Respiratory Diseases
    • /
    • 제75권5호
    • /
    • pp.188-198
    • /
    • 2013
  • Over the past decade, several kinase inhibitors have been approved based on their clinical benefit in cancer patients. Unfortunately, in many cases, patients develop resistance to these agents via secondary mutations and alternative mechanisms. To date, several major mechanisms of acquired resistance, such as secondary mutation of the epidermal growth factor receptor (EGFR) gene, amplification of the MET gene and overexpression of hepatocyte growth factor, have been reported. This review describes the recent findings on the mechanisms of primary and acquired resistance to EGFR tyrosine kinase inhibitors and acquired resistance to anaplastic lymphoma kinase inhibitors, primarily focusing on non-small cell lung carcinoma.

Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia

  • Rattanaburi, Athithan;Boonyapipat, Sathana;Supasinth, Yuthasak
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권12호
    • /
    • pp.5037-5041
    • /
    • 2015
  • Background: An hCG regression curve has been used to predict the natural history and response to chemotherapy in gestational trophoblastic disease. We constructed hCG regression curves in high-risk gestational trophoblastic neoplasia (GTN) treated with EMA/CO and identified an optimal hCG level to detect EMA/CO resistance in GTN. Materials and Methods: Eighty-one women with GTN treated with EMA/CO were classified as primary high-risk GTN (n = 65) and single agent-resistance GTN (n = 16). The hCG levels prior to each course of chemotherapy were plotted in the 10th, 50th, and 90th percentiles to construct the hCG regression curves. Diagnostic performance was evaluated for an optimal cut-off value. Results: The median hCG levels were 264,482 mIU/mL mIU/mL and 495.5 mIU/mL mIU/mL for primary high-risk GTN and single agent-resistance GTN, respectively. The 50th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 4th and the 2nd course of chemotherapy, respectively. The 90th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 9th and the 2nd course of chemotherapy, respectively. The hCG level of ${\geq}118.6mIU/mL$ mIU/mL at the 5thcourse of EMA/CO predicted the EMA/CO resistance in primary high-risk GTN patients with a sensitivity of 85.7% and a specificity of 100%. Conclusion: EMA/CO resistance in primary high-risk GTN can be predicted by using an hCG regression curve in combination with the cut-off value of 118.6 mIU/mL at the 5thcourse of chemotherapy.

Epileptogenic Properties of Balloon Cells in Cortical Tubers of Tuberous Sclerosis : Upregulation of Drug Resistance Proteins

  • Kang, Nam-Gu;Chang, Hong-Joen;Ok, Young-Cheol;Lee, Rae-Seop;Park, Seung-Kyu;Lim, Jun-Seob;Cho, Kyu-Yong;Kim, Hyung-Ihl;Kim, Jae-Hyoo;Oh, Hyun-Sik;Lee, Min-Cheol
    • Journal of Korean Neurosurgical Society
    • /
    • 제41권6호
    • /
    • pp.397-402
    • /
    • 2007
  • Objective : Balloon cells and dysplastic neurons are histopathological hallmarks of the cortical tubers of tuberous sclerosis complex [TSC] and focal cortical dysplasia [FCD] of the Taylor type. They are believed to be the epileptogenic substrate and cause therapeutic drug resistant epilepsy in man. P-glycoprotein [P-gp] is the product of multidrug resistance gene [MDR1], and it maintains intracellular drug concentration at a relatively low level. The authors investigated expression of P-gp in balloon cells and dysplastic neurons of cortical tubers in patients with TSC. Methods : An immunohistochemical study using the primary antibody for P-gp, as an indicative of drug resistance, was performed in the cortical tuber tissues in two patients of surgical resection for epilepsy and six autopsy cases. Results : Balloon cells of each lesion showed different intensity and number in P-gp immunopositivity. P-gp immunopositivity in balloon cells were 28.2%, and dysplastic neurons were 22.7%. These immunoreactivities were more prominent in balloon cells distributed in the subpial region than deeper region of the cortical tubers. Capillary endothelial cells within the cortical tubers also showed P-gp immunopositivity. Conclusion : In this study, the drug resistance protein P-glycoprotein in balloon cells and dysplastic neurons might explain medically refractory epilepsy in TSC.

약제 내성 결핵 환자의 역학적 특징 (Epidemiological Characteristics of Patients with Drug-Resistant Tuberculosis)

  • 이진화;장중현
    • Tuberculosis and Respiratory Diseases
    • /
    • 제49권4호
    • /
    • pp.412-420
    • /
    • 2000
  • 연구배경 : 전세계적으로 약제 내성 결핵에 대한 관심이 높ㅇ지고 있다. 일차 내성 결핵의 유병률은 수년 간의 국가 결핵 관리 체계를 평가하는 역학적 지표로 사용된다. 저자들은 내성 결핵에서의 사회경제적 인자를 포함한 임상적 특정에 대해 평가하고자 하였다. 방법 : 1995년 3월부터 2000년 2월까지 이대목동병원에서 내성 결핵으로 진단 받은 환자 중 조사가 가능했던 68명을 대상으로 하였다. 결과 : 일차 내성 결핵 환자는 획득 내성 결핵환자보다 평균 연령이 더 젊고(39.6$\pm$16.3yr vs. 48.2$\pm$16.5yr ; p<0.05), 40대 미만 연령층의 구성비가 더 높았으며(62.9% vs. 36.4% ; p<0.05), 고학력자가 더 많았다 (38.9% vs. 11.1% ; p<0.05). 획득 내성 환자는 일차 내성 환자보다 통계학적 의의는 없었으나 가족력의 빈도가 더 높고 자가 주택이 없는 경우가 더 많았다. 획득 내성 환자는 일차 내성 환자보다 침범된 폐엽의 수가 더 많았고(2.0$\pm$0.8 vs. 1.4$\pm$0.7; p<0.01), 총 치료 기간이 더 길었다(18.3$\pm$7.2 months vs. 10.6$\pm$6.3 months ; p<0.05). 획득 내성 환자가 일차 내성 환자보다 통계학적 의의는 없었으나 내성 약제의 수가 더 많고 입원률이 더 낮았으며 임의로 투약을 중단하는 경우가 더 많았다. 일차 내성 환자가 획득 내성 환자보다 단일 약제 내성률이 더 높은 반면, 복수 약제 내성률과 다제 내성률은 더 낮았다. 약제별 내성률에서 isoniazid에 대한 내성률이 가장 높았고, 획득 내성 환자에서 일차 내성 환자보다 isoniazid에 대한 내성률이 유의하게 높았다(90.9% vs. 71.4% ; p<0.05). 결론 : 획득 내성 환자가 낮은 사회경제적 계층의 비율이 높은 반면, 일차 내성 환자는 젊고 활동적인 집단인 것으로 보인다. 약제 내성 결핵의 전파와 재발을 막기 위해서는 내성 환자의 적절한 격리와 적극적인 추적 관찰을 통한 치료의 종결이 중요하다.

  • PDF

Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide

  • Kanno, Toshiyuki;Matsui, Hideo;Akizawa, Yoshika;Usui, Hirokazu;Shozu, Makio
    • Journal of Gynecologic Oncology
    • /
    • 제29권6호
    • /
    • pp.89.1-89.8
    • /
    • 2018
  • Objective: Highly effective chemotherapy for patients with low-risk gestational trophoblastic neoplasia (GTN) is associated with almost a 100% cure rate. However, 20%-30% of patients treated with chemotherapy need to change their regimens due to severe adverse events (SAEs) or drug resistance. We examined the treatment outcomes of second-line chemotherapy for patients with low-risk GTN. Methods: Between 1980 and 2015, 281 patients with low-risk GTN were treated. Of these 281 patients, 178 patients were primarily treated with 5-day intramuscular methotrexate (MTX; n=114) or 5-day drip infusion etoposide (ETP; n=64). We examined the remission rates, the drug change rates, and the outcomes of second-line chemotherapy. Results: The primary remission rates and drug resistant rates of 5-day ETP were significantly higher (p<0.001) and significantly lower (p=0.002) than those of 5-day MTX, respectively. Forty-seven patients (26.4%) required a change in their chemotherapy regimen due to the SAEs (n=16) and drug resistance (n=31), respectively. Of these 47 patients failed the first-line regimen, 39 patients (39/47, 82.9%) were re-treated with single-agent chemotherapy, and 35 patients (35/39, 89.7%) achieved remission. Four patients failed second-line, single-agent chemotherapy and eight patients (17.0%) who failed first-line regimens were treated with combined or multi-agent chemotherapy and achieved remission. Conclusions: Patients with low-risk GTN were usually treated with single-agent chemotherapy, while 20%-30% patients had to change their chemotherapy regimen due to SAEs or drug resistance. The second-line regimens of single-agent chemotherapy were effective; however, there were several patients who needed multiple agents and combined chemotherapy to achieve remission.

일차진료 항생제 치료기간과 비인두 항생제 내성률에 대한 연구 고찰 (A Review of Studies on Antibiotic Course and Antibiotic Resistance in Nasopharyngeal Pathogens in Primary Care Setting)

  • 신향화;이선행;윤성중;장규태
    • 대한한방소아과학회지
    • /
    • 제32권2호
    • /
    • pp.64-71
    • /
    • 2018
  • Objectives The purpose of this study is to examine the correlation of antibiotics administration duration and antimicrobial resistance by reviewing domestic and foreign literatures. Methods We searched literatures dated up to 23 February, 2018 in PubMed and Cochrane Library using terms of "Anti-Bacterial Agents", "Carrier State", "Nasopharynx", "Drug Administration Schedule", and also searched via RISS (Research Information Service System), KISS (Koreanstudies Information Service System), DBpia (DataBase Periodical Information Academic) using terms of antibiotics, resistance, and dose. Results In comparison with shortened and standard antibiotic course, longer treatment duration is associated with greater antimicrobial resistance or non-significant difference, but we cannot find literature that shortened antibiotic course increases antimicrobial resistance on human nasopharyngeal flora. Conclusions Currently, there is no evidence that completing the standard antibiotic course reduces antimicrobial resistance. It can be a strategy for reducing antibiotic use to apply Korean medicine treatment, as well as short-course antibiotic therapy or delayed antibiotic prescription. Additional well-designed trials should be conducted in domestic and foreign settings about the appropriate duration of antibiotic therapy.

TROGLITAZONE, A NOVEL ANTIDIABETIC DRUG -NEW AVENUE FOR TREATING INSULIN RESISTANCE-

  • Horikoshi, Hiroyoshi
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 1998년도 춘계학술대회
    • /
    • pp.1-4
    • /
    • 1998
  • Impaired insulin action in Type 2 diabetes is thought to lead to hyperglycemia, with both environmental and complex genetic factors playing key roles. Although the primary lesion in Type 2 diabetes is unknown, a number of studies suggest that metabolic defects in the liver, skeletal muscle and fat, and pancreatic ${\beta}$-cells contribute to the disease. These metabolic abnormalities are characterized by the overproduction of hepatic glucose, impaired insulin secretion, and peripheral insulin resistance. In current pharmacological treatment of Type 2 diabetes, sulfonylurea (SU) drugs have mainly been used as oral hypoglycemic drugs to stimulate endogenous insulin secretion from ${\beta}$ cells. SU drugs, however, sometimes aggravate the disease by causing fatigue of the pancreatic ${\beta}$ cells, which leads to reduced drug efficacy after long-term treatment. This class of drugs also leads to enhanced obesity arising from the stimulation of endogenous insulin secretion in obese Type 2 diabetic patients, plus an increased incidence of SU-induced hypoglycemia. Since 1980, a major challenge has been made by us to develop a potential pharmacological therapy for the treatment of insulin resistance in peripheral tissues and/or suppression of abnormal hepatic glucose production in Type 2 diabetic patients. Such a drug would be expected to have fewer side effects and retain long-term efficacy.

  • PDF

Prevalence of Drug Resistance-Associated Gene Mutations in Plasmodium vivax in Central China

  • Lu, Feng;Wang, Bo;Cao, Jun;Sattabongkot, Jetsumon;Zhou, Huayun;Zhu, Guoding;Kim, Kwonkee;Gao, Qi;Han, Eun-Taek
    • Parasites, Hosts and Diseases
    • /
    • 제50권4호
    • /
    • pp.379-384
    • /
    • 2012
  • Resistance of Plasmodium spp. to anti-malarial drugs is the primary obstacle in the fight against malaria, and molecular markers for the drug resistance have been applied as an adjunct in the surveillance of the resistance. In this study, we investigated the prevalence of mutations in pvmdr1, pvcrt-o, pvdhfr, and pvdhps genes in temperate-zone P. vivax parasites from central China. A total of 26 isolates were selected, including 8 which were previously shown to have a lower susceptibility to chloroquine in vitro. For pvmdr1, pvcrt-o, and pvdhps genes, no resistance-conferring mutations were discovered. However, a highly prevalent (69.2%), single-point mutation (S117N) was found in pvdhfr gene. In addition, tandem repeat polymorphisms existed in pvdhfr and pvdhps genes, which warranted further studies in relation to the parasite resistance to antifolate drugs. The study further suggests that P. vivax populations in central China may still be relatively susceptible to chloroquine and sulfadoxine-pyrimethamine.